The efficacy and safety of Ad-mediated intrapleural delivery of Interferon α-2b (rAd-IFN) in combination with celecoxib and gemcitabine in patients with mesothelioma (epithelioid or biphasic histology), who have failed previous treatments, is currently being evaluated in a phase III, open-label, randomized study. The gene discussed is IFNA1; the disease is mesothelioma.